Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance

Drug Delivery

Volumn 19, Issue 8, 2012, Pages 363-370

  Sarisozen, Can ^a   Vural, Imran ^a   Levchenko, Tatyana ^b   Hincal, A Atilla ^a   Torchilin, Vladimir P ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Co loading; Elacridar; Micelles; Multidrug resistance; Paclitaxel

Indexed keywords

ALPHA TOCOPHEROL; DRUG CARRIER; ELACRIDAR; MACROGOL; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; IN VITRO STUDY; MICELLE; MULTIDRUG RESISTANCE; PARTICLE SIZE; PRIORITY JOURNAL;

ACRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; HUMANS; MICELLES; P-GLYCOPROTEIN; PACLITAXEL; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SOLUBILITY; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 84870152480     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.724473     Document Type: Article

References (56)

1. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000;60:5761-5766.
2. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release 2007;122:324-330. (Pubitemid 47404677)
3. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001;296:551-557. (Pubitemid 32112485)
4. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302. (Pubitemid 30662093)
5. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-592. (Pubitemid 34800230)
6. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrugresistant human cells. Cell 1986;47:381-389. (Pubitemid 17210152)
7. Cho YW, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release 2004;97:249-257. (Pubitemid 38759482)
8. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005;32:S9-15.
9. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 2006;315:148-157. (Pubitemid 43674120)
10. Diezi TA, Kwon G. Amphotericin B/sterol co-loaded PEG-phospholipid micelles: effects of sterols on aggregation state and hemolytic activity of amphotericin B. Pharm Res 2012;29:1737-1744.
11. Foxwell BM, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989;36:543-546. (Pubitemid 19273829)
12. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target 2003;11:87-92. (Pubitemid 36869181)
13. Goddard ED, Turro NJ, Kuo PL, Ananthapadmanabhan KP. Fluorescence probes for critical micelle concentration determination. Langmuir 1985;1:352-355. (Pubitemid 15508305)
14. Gottesman MM, Ambudkar SV, Ni B, Aran JM, Sugimoto Y, Cardarelli CO, Pastan I. Exploiting multidrug resistance to treat cancer. Cold Spring Harb Symp Quant Biol 1994;59:677-683.
15. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627. (Pubitemid 34177898)
16. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-4602. (Pubitemid 23304385)
17. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 1999;88:28-33. (Pubitemid 29037364)
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
19. Jule E, Yamamoto Y, Thouvenin M, Nagasaki Y, Kataoka K. Thermal characterization of poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles based on pyrene excimer formation. J Control Release 2004;97:407-419. (Pubitemid 38802943)
20. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
21. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54:759-779. (Pubitemid 35247525)
22. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-283.
23. Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000;85:131-141.
24. Lage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interferencemediated reversal of multidrug resistance. Curr Drug Targets 2006;7:813-821.
25. Lee J, Lee SC, Acharya G, Chang CJ, Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res 2003;20:1022-1030. (Pubitemid 36774273)
26. Li X, Li P, Zhang Y, Zhou Y, Chen X, Huang Y, Liu Y. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 2010;27:1498-1511.
27. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycoldiacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res 2002;19:1424-1429. (Pubitemid 35266545)
28. Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBRligand: synergistic anticancer effect. Mol Pharm 2009;6:468-479.
29. Neumann M, Wilisch A, Diddens H, Probst H, Gekeler V. MDR hamster cells exhibiting multiple altered gene expression: effects of dexniguldipine-HCl (B859-35), cyclosporin A and buthionine sulfoximine. Anticancer Res 1992;12:2297-2302. (Pubitemid 23105449)
30. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-7295. (Pubitemid 37487160)
31. Patel NR, Rathi A, Mongayt D, Torchilin VP. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 2011;416:296-299.
32. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136:21-29.
33. Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP. PEGPE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. Drug Deliv 2012;19:169-176.
34. Sauna ZE, Ambudkar SV. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 2001;276:11653-11661.
35. Sawant RR, Sawant RM, Torchilin VP. Mixed PEG-PE/vitamin E tumortargeted immunomicelles as carriers for poorly soluble anticancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur J Pharm Biopharm 2008;70:51-57.
36. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94:4028-4033. (Pubitemid 27180493)
37. Shabbits JA, Krishna R, Mayer LD. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 2001;1:585-594. (Pubitemid 34685466)
38. Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, Hou SX, Xiong SJ, Lei XJ, Wei YQ. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009;37:300-305.
39. Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 1999;10:719-728. (Pubitemid 30015673)
40. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 1994;86:688-694. (Pubitemid 24138974)
41. Stein WD, Cardarelli C, Pastan I, Gottesman MM. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 1994;45:763-772. (Pubitemid 24139206)
42. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234. (Pubitemid 43336035)
43. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 2002;19:765-772. (Pubitemid 34686734)
44. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001;73:137-172. (Pubitemid 32544594)
45. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003;100:6039-6044. (Pubitemid 36576927)
46. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005;2:319-327. (Pubitemid 41282750)
47. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620-3626. (Pubitemid 28376560)
48. Trubetskoy VS, Torchilin VP. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv Drug Deliv Rev 1995;16:311-320.
49. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a fulllength cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-3008. (Pubitemid 17064766)
50. Walle UK, Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 1998;26:343-346. (Pubitemid 28201244)
51. Wang J, Goh B, Lu W, Zhang Q, Chang A, Liu XY, Tan TM, Lee H. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 2005;28:822-828. (Pubitemid 40740648)
52. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res 1998;15:1552-1556. (Pubitemid 28465741)
53. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 1996;2:7-12. (Pubitemid 26046497)
54. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrugresistant breast cancer. J Control Release 2006;116:275-284. (Pubitemid 44827405)
55. Zhang W, Shi Y, Chen Y, Yu S, Hao J, Luo J, Sha X, Fang X. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 2010;75:341-353.
56. Zhao CL, Winnik MA, Riess G, Croucher MD. Fluorescence probe techniques used to study micelle formation in water-soluble block copolymers. Langmuir 1990;6:514-516. (Pubitemid 20663816)